Merck KGaA Non-GAAP EPS of €2.32, revenue of €5.63B; raises FY2026 outlook
Merck KGaA Non-GAAP EPS of €2.32, revenue of €5.63B; raises FY2026 outlook(摘要待生成)
Merck outlines 2026 revenue of $66.8B-$67.3B and EPS of $2.77-$2.82 while investing ahead of KEYTRUDA LOE
Merck outlines 2026 revenue of $66.8B-$67.3B and EPS of $2.77-$2.82 while investing ahead of KEYTRUDA LOE(摘要待生成)
Pharma giants Merck, Eli Lilly face earnings health check
Pharma giants Merck, Eli Lilly face earnings health check(摘要待生成)
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus - Yahoo Finance
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus - Yahoo Finance(摘要待生成)
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher - Yahoo Finance
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher - Yahoo Finance(摘要待生成)
Biopharma stocks climb on Merck and Eli Lilly earnings - CNBC
Biopharma stocks climb on Merck and Eli Lilly earnings - CNBC(摘要待生成)
Merck (MRK) Q3 2026 Earnings Call Transcript
Merck reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year. [[fact-7h28o1xt8]] Third-quarter earnings per share were $2.49, including a $0.12-per-share charge related to a license agreement. [[fact-8s5ozc6jm]] Sales of the KEYTRUDA family of products increased 6% to $8.6 billion. [[fact-osp00qw1p]] Gardasil sales were $2 billion, an increase of 14%. [[fact-2v3avdx2q]] The company expects 2026 revenue of $66.8 billion to $67.3 billion, representing growth of 3% to 4%. [[fact-zqfwzt7pi]]
Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction - Yahoo Finance
Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction - Yahoo Finance(摘要待生成)
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up - Yahoo Finance
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up - Yahoo Finance(摘要待生成)
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength(摘要待生成)
Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers.
Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers.(摘要待生成)
Merck MASH asset efinopegdutide meets primary goal in mid-stage trial
Merck MASH asset efinopegdutide meets primary goal in mid-stage trial(摘要待生成)
Merck exits U.S. CDMO operations in sale to Lonza
Merck exits U.S. CDMO operations in sale to Lonza(摘要待生成)
FDA Rejects Summit's China-Developed Merck Rival; Shares Dive
FDA Rejects Summit's China-Developed Merck Rival; Shares Dive Investor's Business Daily
Merck shares hit over 1-year high as Q3 beats estimates and outlook is raised
Merck shares hit over 1-year high as Q3 beats estimates and outlook is raised(摘要待生成)
Merck Stocks Decline With Higher Target Leaving a New-Launch Scale Test - Yahoo Finance
Merck Stocks Decline With Higher Target Leaving a New-Launch Scale Test - Yahoo Finance(摘要待生成)
Why Merck Stock Flew Higher on Friday - Yahoo Finance
Why Merck Stock Flew Higher on Friday - Yahoo Finance(摘要待生成)
Guggenheim raises Merck stock price target to $171 on Q3 beat
Guggenheim raises Merck stock price target to $171 on Q3 beat(摘要待生成)